 |
Photo = Bukwang Pharmaceutical |
[Alpha Biz= Reporter Kim Sangjin] Bukwang Pharm has decided to halt the U.S. clinical trials for its Parkinson's disease treatment, JM-010, developed by its subsidiary Contera Pharma.
On the 23rd, Bukwang Pharm held a corporate briefing regarding the results of the late-stage Phase 2 clinical trial of JM-010. According to CEO Lee Jae-young, while there was a statistically significant difference before and after treatment with JM-010, the difference was not statistically significant compared to the placebo group. There were no serious or unexpected adverse reactions in terms of safety.
Currently, Bukwang Pharm is conducting additional analyses on secondary endpoints and subgroups. Some subgroups showed statistically significant differences compared to the placebo. Detailed results will be presented at future conferences.
Bukwang Pharm had been conducting both European and U.S. clinical trials up until recently. The initial strategy was to transition from the ongoing Phase 2 trial in the U.S. to Phase 3 based on the results of Contera Pharma's Phase 2 trial. However, due to the failure to meet the primary endpoint and considering the project's business viability, the company decided to discontinue the U.S. clinical trial as well.
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
